The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on m...

Full description

Bibliographic Details
Main Authors: Virginia Liberini, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, Désirée Deandreis
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Diagnostics
Subjects:
peptide receptor radionuclide therapy
PRRT
68Ga-labeled somatostatin analogue
18F-FDG
response assessment
RECIST
Online Access:https://www.mdpi.com/2075-4418/10/12/1083

Internet

https://www.mdpi.com/2075-4418/10/12/1083

Similar Items